AGM/EGMJun 1, 2026, 04:22 PM
Esperion Stockholders Approve 7M Share Increase for 2022 Incentive Plan
AI Summary
Esperion Therapeutics, Inc. held its 2026 annual meeting of stockholders on May 28, 2026. Key outcomes included the approval of an amendment to the 2022 Stock Option and Incentive Plan, increasing the aggregate number of shares authorized for issuance by 7,000,000. Stockholders also elected two Class I directors, approved the non-binding advisory resolution on executive compensation, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Stockholders approved an amendment to the 2022 Stock Option and Incentive Plan, increasing authorized shares by 7,000,000.
- J. Martin Carroll was elected as a Class I director with 105,082,565 votes For.
- Sheldon L. Koenig was elected as a Class I director with 109,672,941 votes For.
- The non-binding advisory resolution on executive compensation was approved with 95,650,226 votes For.
- The appointment of Ernst & Young LLP as independent auditor for 2026 was ratified with 167,083,447 votes For.
- The 2022 Plan amendment passed with 108,150,213 votes For.
Price Impact
More from ESPR